JP Morgan

Enzene is redefining the future of biologics manufacturing — and at JPM we look forward to engaging with leaders and investors who believe scalable innovation is the next strategic advantage in biopharma.

Join us to:

– Experience our Fully Connected Continuous Manufacturing™ (FCCM) platform — engineered for maximum process intensification, operational efficiency, and cGMP compliance.

– Explore robust, scalable strategies for tech transfer, process resilience, and accelerated commercial readiness.

Connect with our Leadership to discuss how Enzene’s end-to-end CDMO capabilities can unlock smarter, faster pathways from development to large-scale production.